[Primary drug resistance of Mycobacterium tuberculosis in patients with new-onset destructive pulmonary tuberculosis].
In 2005-2007, primary drug resistance of Mycobacterium tuberculosis (MBT) was studied in 1318 patients with new-onset destructive pulmonary tuberculosis. This was identified in 31.8, 28.5, and 29.1% in 2005, 2006, and 2007, respectively. During these years, there was an increase in the primary rifampicin resistance of MBT from 28.8% in 2005 to 37.7% in 2007. Primary streptomycin resistance was 100% in 2007. The authors consider the primary resistance of MBT as a priority problem of phthisiology.
Zinov'ev
I P
IP
Esaulova
N A
NA
Novikov
V G
VG
Kokovikhina
I A
IA
D000995:Antitubercular Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D011379:Prognosis; D012189:Retrospective Studies; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents